May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
Persistency With Topical Prostaglandin Therapy in Glaucoma Management
Author Affiliations & Notes
  • G.F. Schwartz
    Glaucoma Consultants, Greater Baltimore Medical Center; Wilmer Eye Institute, Johns Hopkins University; University of Maryland, Baltimore, MD, United States
  • G. Reardon
    Informagenics, LLC, Worthington, OH, United States
  • E. Mozaffari
    Pharmacia Corporation, Peapack, NJ, United States
  • Footnotes
    Commercial Relationships  G.F. Schwartz, Pharmacia Corporation R; Allergan, Inc. C, R; Merck & Company, Inc. R; G. Reardon, Pharmacia Corporation C; E. Mozaffari, Pharmacia Corporation E.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 173. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G.F. Schwartz, G. Reardon, E. Mozaffari; Persistency With Topical Prostaglandin Therapy in Glaucoma Management . Invest. Ophthalmol. Vis. Sci. 2003;44(13):173.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: The purpose of this research was to evaluate persistency (time on therapy) with prostaglandin analogues in the treatment of glaucoma or ocular hypertension. Methods: This population-based, retrospective cohort study used the Protocare Sciences claims database, which includes prescription and medical claims data from multiple managed care organizations. Patients ≥20 years of age who initiated therapy with latanoprost, bimatoprost, or travoprost between April 2001 and June 2002 were included. Patients were required to be continuously enrolled for the 180 days prior to index prescription fill. Follow-up continued through June 30, 2002. Two outcome measures were analyzed: 1) discontinuation of the index prostaglandin and 2) either discontinuation or change in the index prostaglandin regimen. Changing therapy was defined as switching to or adding another ocular hypotensive. Cox regression models were used to compare rates of discontinuation and discontinuation/change. Patient data were censored upon termination of insurance coverage or at the end of the study period. Results: In all, 7527 patients were prescribed a prostaglandin analogue, and 4356 patients met the inclusion criteria (n = 2376, 993, and 987 for latanoprost, bimatoprost, and travoprost, respectively). Compared to latanoprost, those treated with bimatoprost were 38% more likely to discontinue and 31% more likely to discontinue/change therapy, and patients treated with travoprost were 36% more likely to discontinue and 29% more likely to discontinue/change therapy (P < 0.001 for each comparison). Conclusions: This is the first study to compare persistency with therapy in patients treated with one of these three prostaglandin analogues. Latanoprost-treated patients demonstrated significantly greater persistency than did those treated with either bimatoprost or travoprost.

Keywords: clinical (human) or epidemiologic studies: hea • clinical (human) or epidemiologic studies: out 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.